LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation for ADX-2191 (methotrexate intravitreal injection, USP) for the t…
Category: News
Pill That Slows Aging? Meds May Boost Health Span
Metformin, rapamycin, and senolytics show multifaceted effects on aging biology that could transform how clinicians approach chronic disease prevention. Medscape Medical News
AMD Light Therapy Restores Vision Gains Post-Treatment Pause
A tabletop light therapy device led to vision improvements over 4.5 years and a long pause between treatments in people with dry age-related macular degeneration. Medscape Medical News
jCyte Inc. Announces First Patients Treated in JC02-88 Trial for Retinitis Pigmentosa
NEWPORT BEACH, Calif.–(BUSINESS WIRE)–jCyte, Inc. is pleased to announce the first patients have been enrolled and treated in the JC02-88 study evaluating the safety and efficacy of jCell (famzeretcel) for the treatment of retinitis pigmentosa (RP). …
Long-Term Use of Metformin May Prevent AMD in Diabetes
Patients with diabetes who use metformin for at least 5 consecutive years are less likely to develop AMD, particularly the dry type, a recent study shows. Medscape Medical News
FDA Approves New ADC for Lung Cancer Treatment
Dr Mark Kris discusses datopotamab deruxtecan as a potent option post-osimertinib but warns of toxicity patterns unfamiliar to many lung oncologists. Medscape Oncology
Saudi Arabia OTC Artificial Tears Market Report 2025-2033 | Vision 2030 Boosts Retail and Online Channels, Non-Prescription Eye Care Boom Fuels Expansion – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Saudi Arabia OTC Artificial Tears Market – Demand & Forecast 2025-2033” report has been added to ResearchAndMarkets.com’s offering. Saudi Arabia OTC Artificial Tears Market is expected to reach US$ 79.09 million by 203…
Simple, Noninvasive Eye Tracking May Flag Cognitive Decline
Naturalistic gaze patterns appear to be a simple, noninvasive, and reliable indicator of cognitive decline, new research suggests. Medscape Medical News
Bausch + Lomb to Participate in Upcoming Investor Conferences
VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that members of its management team will participate in two invest…
Glaukos Announces Participation in Wells Fargo Healthcare Conference
ALISO VIEJO, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that i…
Does This Side Effect Spell Doom for the GLP-1’s?
The increased risk for a rare optic nerve disorder may not tarnish the game-changer reputation of the GLP-1 drugs. Medscape
Does This Side Effect Spell Doom for the GLP-1s?
The increased risk for a rare optic nerve disorder may not tarnish the game-changer reputation of the GLP-1 drugs. Medscape
First FDA-Approved Treatment for MacTel Performed
CUMBERLAND, R.I.–(BUSINESS WIRE)–Neurotech Pharmaceuticals, Inc., a private biotech company focused on developing transformative therapies for chronic eye diseases, announced the first commercial manufacturing, shipment, and surgical procedure for EN…
New Anti-VEGF Agents Extend Dosing Intervals in Wet AMD
New anti-VEGF agents for wet age-related macular degeneration can extend injection intervals to 3-5 months but may increase inflammation risk, prompting calls for tailored treatment plans. Medscape Medical News
Rare Eye Disease Gets First NHS Drug Recommendation
NICE’s recommendation of idebenone (Raxone) for Leber hereditary optic neuropathy offers hope for patients against visual impairment. Medscape News UK
Study Counters Others on GLP-1, Diabetic Retinopathy Link
An observational study of 160,000 patients with diabetes taking GLP-1 drugs finds no heightened risk for retinopathy complications. Medscape Medical News
Study Counters Others on GLP-1, Diabetic Retinopathy Link
An observational study of 160,000 patients with diabetes taking GLP-1 drugs finds no heightened risk for retinopathy complications. Medscape Medical News
Warby Parker Announces Second Quarter 2025 Results
NEW YORK–(BUSINESS WIRE)–Warby Parker Inc. (NYSE: WRBY) (“Warby Parker” or the “Company”), a direct-to-consumer lifestyle brand focused on vision for all, today announced financial results for the second quarter ended June 30, 2025. “It has been a bu…
As Copay Aid Recedes, Retina Treatment ‘Unsustainable’
A new study finds cuts in copay assistance for retina injections are harming lower-income communities and leading to poorer vision outcomes. Medscape Medical News
STAAR Surgical Reports Second Quarter 2025 Results
LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the second quarter ended June…